BackgroundCheck.run
Search For

Robert A Babb, 63The Villages, FL

Robert Babb Phones & Addresses

The Villages, FL   

2803 Roderick Rd, Frederick, MD 21704    240-4091247   

New York, NY   

Annapolis, MD   

2803 Roderick Rd, Frederick, MD 21704    301-8311066   

Work

Position: Administrative Support Occupations, Including Clerical Occupations

Education

School / High School: The University of Melbourne Law School

Ranks

Licence: New York - Currently registered Date: 2008

Mentions for Robert A Babb

Career records & work history

Lawyers & Attorneys

Robert Babb Photo 1

Robert Lee Babb - Lawyer

Address:
National Australia Bank Limited
322-65xxxxx (Office)
Licenses:
New York - Currently registered 2008
Education:
The University of Melbourne Law School
Robert Babb Photo 2

Robert Babb - Lawyer

ISLN:
909329813
Admitted:
1949
Law School:
Wake Forest College and University of Richmond, LL.B., 1949

Medicine Doctors

Robert Babb Photo 3

Robert Edgar Babb

Specialties:
Internal Medicine
Gastroenterology
Sports Medicine
Education:
University of South Carolina(1970)

License Records

Robert Lee Babb

Licenses:
License #: 10350 - Expired
Category: Contractor
Expiration Date: Jan 31, 2010

Resumes & CV records

Resumes

Robert Babb Photo 48

Letter Carrier

Location:
Frederick, MD
Industry:
Government Administration
Work:
United States Postal Service
Letter Carrier
Robert Babb Photo 49

Robert Babb

Robert Babb Photo 50

Robert Babb

Robert Babb Photo 51

Robert Babb

Publications & IP owners

Us Patents

Common Light Chain Mouse

US Patent:
2012019, Jul 26, 2012
Filed:
Mar 6, 2012
Appl. No.:
13/412936
Inventors:
Robert Babb - River Edge NJ, US
John McWhirter - Tarrytown NY, US
Lynn MacDonald - White Plains NY, US
Sean Stevens - San Francisco CA, US
Samuel Davis - New York NY, US
David R. Buckler - Chester NJ, US
Andrew J. Murphy - Croton-on-Hudoson NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A01K 67/027
US Classification:
800 18
Abstract:
A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making light chain variable regions in mice, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, are provided.

Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain

US Patent:
2013004, Feb 21, 2013
Filed:
Jun 5, 2012
Appl. No.:
13/488628
Inventors:
Robert Babb - River Edge NJ, US
John McWhirter - Tarrytown NY, US
Lynn MacDonald - White Plains NY, US
Sean Stevens - San Francisco CA, US
Samuel Davis - New York NY, US
David R. Buckler - Chester NJ, US
Andrew J. Murphy - Croton-on-Hudson NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
C12P 21/00
G01N 21/64
G01N 33/566
US Classification:
435 792, 436501, 435 696
Abstract:
A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.

Enhanced Expression And Stability Regions

US Patent:
2013013, May 23, 2013
Filed:
Jan 29, 2013
Appl. No.:
13/752647
Inventors:
ROBERT BABB - Nanuet NY, US
JAMES P. FANDL - LaGrangeville NY, US
Assignee:
REGENERON PHARMACEUTICALS, INC. - Tarrytown NY
International Classification:
C12N 15/85
US Classification:
435328, 435326, 435 696
Abstract:
Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (EESYRs) are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.

Methods For Obtaining Antibodies That Bind Transmembrane Proteins And Cells That Produce The Same

US Patent:
2022019, Jun 23, 2022
Filed:
Dec 22, 2021
Appl. No.:
17/558645
Inventors:
- Tarrytown NY, US
Ergang Shi - Sleepy Hollow NY, US
Wen-Yi Lee - New Hyde Park NY, US
David Suh - Midland Park NJ, US
Glen Farr - Prospect CT, US
Robert Babb - River Edge NJ, US
International Classification:
C07K 16/28
G01N 33/68
Abstract:
Disclosed are methods for obtaining cells that express antibodies that bind transmembrane proteins, methods for generating antibodies from such cells, antibodies to transmembrane proteins and fragments thereof, and nucleic acids encoding the antibodies. More particularly, the disclosure relates to methods for obtaining antibody-producing cells that express an antibody that binds to a transmembrane protein based on the use of lipid bilayer-membrane scaffold protein complexes to present transmembrane protein antigens to cells.

Optimized Anti-Cd3 Bispecific Antibodies And Uses Thereof

US Patent:
2021025, Aug 19, 2021
Filed:
Mar 19, 2021
Appl. No.:
17/207462
Inventors:
- Tarrytown NY, US
Lauric Haber - Rye Brook NY, US
Robert Babb - River Edge NJ, US
Gang Chen - Yorktown Heights NY, US
Douglas MacDonald - New York NY, US
International Classification:
C07K 16/28
C07K 16/30
A61P 35/00
C07K 16/40
C07K 16/46
Abstract:
The present invention provides antibodies that bind to CD3 with weak or no detectable binding affinity and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with low affinity and induce human T cell proliferation and hence induce T cell-mediated killing of tumor cells with high efficacy. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3 with weak or no detectable binding affinity in an in vitro assay, and a second antigen-binding molecule that specifically binds human tumor-associated antigen. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing target antigen, such as PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers or other diseases where immunotherapy, i.e. effector cell immunomodulation is warranted.

Method For Generating High Affinity Antibodies

US Patent:
2020036, Nov 26, 2020
Filed:
Aug 7, 2020
Appl. No.:
16/987639
Inventors:
- Tarrytown NY, US
Robert BABB - River Edge NJ, US
James P. FANDEL - LaGrangeville NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
C07K 16/32
C07K 16/00
C07K 16/22
G01N 33/50
Abstract:
The present disclosure relates to a method for identifying cells that express antigen-specific antibodies with a high binding affinity for a monomeric antigen. Using fluorescence activated cell sorting, cells expressing high affinity antigen-specific antibodies are selected from a population of immune cells isolated from a mammal that has been immunized with or otherwise exposed to the antigen. Nucleic acids encoding the high affinity antibodies can then be cloned into other lymphoid and non-lymphoid cells where the antibody can be expressed and from which the antibodies can be secreted.

Enhanced Expression And Stability Regions

US Patent:
2018032, Nov 15, 2018
Filed:
Mar 9, 2018
Appl. No.:
15/916349
Inventors:
- Tarrytown NY, US
Robert Babb - Nanuet NY, US
James P. Fandl - LaGrangeville NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
C12N 15/85
C07K 16/00
Abstract:
Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (EESYRs) are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.

Method For Generating High Affinity Antibodies

US Patent:
2017032, Nov 16, 2017
Filed:
Nov 13, 2015
Appl. No.:
15/526522
Inventors:
- Tarrytown NY, US
Robert BABB - River Edge NJ, US
James P. FANDL - LaGrangeville NY, US
International Classification:
C07K 16/32
G01N 33/50
C07K 16/22
C07K 16/00
Abstract:
The present disclosure relates to a method for identifying cells that express antigen-specific antibodies with a high binding affinity for a monomeric antigen. Using fluorescence activated cell sorting, cells expressing high affinity antigen-specific antibodies are selected from a population of immune cells isolated from a mammal that has been immunized with or otherwise exposed to the antigen. Nucleic acids encoding the high affinity antibodies can then be cloned into other lymphoid and non-lymphoid cells where the antibody can be expressed and from which the antibodies can be secreted.

Isbn (Books And Publications)

Programming Parallel Processors

Author:
Robert Babb
ISBN #:
0201117215

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.